With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.192130-34-0,tert-Butyl 4-(2-aminoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
In THF (50 mL) were dissolved 4-((3-chloro-4-methoxybenzyl)amino)-2-(5-azaspiro [2.4]heptan-5-yl)pyrimidine-5-carboxylic acid (1.0 g, 2.58 mmol), tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate (709 mg, 3.1 mmol) and HATU (1.18 g, 3.09 mmol). DIEA (1 mL, 5.16mmol) was added. The reaction was conducted at ambient temperature for 8 h. The solvent was removed, and DCM (50 mL) was added for resolution. The DCM phase was washed with water (50 mLx3). The organic phase was dried, concentrated and purified by silica gel column chromatography (DCM / methanol = 150/1) to give tert-butyl 4-(2-(4-((3-chloro-4-methoxybenzyl)amino)-2-(5-azaspiro[2.4]heptan-5-yl) pyrimidine-5-formamido)ethyl)piperazine-1-carboxylate as a white solid (910 mg, 59 percent yield)., 192130-34-0
As the paragraph descriping shows that 192130-34-0 is playing an increasingly important role.
Reference£º
Patent; Xuanzhu Pharma Co., Ltd.; WU, Frank; WANG, Aichen; EP2886540; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics